Results for tag: "Cerebrotendinous Xanthomatosis Drug"

Cerebrotendinous Xanthomatosis (CTX) is a rare genetic disorder caused by a deficiency of the enzyme sterol 27-hydroxylase. It is characterized by the accumulation of cholesterol and other lipids in the body, leading to neurological, ophthalmological, and musculoskeletal symptoms. Treatment of CTX is focused on reducing the levels of cholesterol and other lipids in the body. Endocrine and Metabolic Disorders Drugs are used to treat CTX, including statins, bile acid sequestrants, and fibrates. These drugs work by blocking the absorption of cholesterol in the intestines, reducing the amount of cholesterol in the body. The Cerebrotendinous Xanthomatosis Drug market is a niche market, with a limited number of drugs available for treatment. Companies in the market include Pfizer, Merck, Sanofi, and Novartis. These companies are involved in the research and development of new drugs for the treatment of CTX, as well as the marketing and distribution of existing drugs. Show Less Read more